Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Anti-stroke drug effective treatment for middle-ear infections, researchers say

  • Implantable micro-device to monitor oxygen in glioma to improve treatment outcomes

  • Study on neurogenesis in the olfactory bulb

  • Raising a glass to the holidays: Research finds extra alcohol sold, consumed on holidays

  • Human stem cell model reveals molecular cues critical to neurovascular unit formation

  • Scientists create mice with a major genetic cause of ALS, frontotemporal dementia

  • Blood test for Alzheimer's one step closer

  • Switching off brain circuit renders mice 'out of touch' with environment

  • Facebook status updates reveal low self-esteem and narcissism

  • Anticipating temptation may reduce unethical behavior, research finds

  •